New Developments in Prostate Cancer Screening Using a Novel Cancer-Specific, non-PSA Biomarker Assay

(Excerpts from the OAT Journal:

In the United States, prostate cancer is the most common non-skin related cancer in among men, with an estimated 161,360 new cases and 26,730 deaths in 2017.
Since the 1980’s, widespread screening with serum prostate-specific antigen (PSA) levels and digital rectal examination (DRE) have facilitated early detection and there has been a significant decline in prostate cancer mortality. However, PSA testing lacks specificity for high-grade disease, leading to a high rate of false-positive results and unnecessary, repeat biopsies, which pose the risk for bleeding, infection, and pain. In addition, harms of over diagnosis and treatment, stemming from PSA testing include, infection, blood loss requiring transfusion, pneumonia, erectile dysfunction, and incontinence. Furthermore, patient anxiety may result from false-positive results of PSA testing as well as having to undergo prostate biopsy.

The discovery that patients with cancer produce detectable autoantibodies against antigens in their tumors suggests that biomarkers could have diagnostic and prognostic value. Building upon these findings, researchers identified a panel of eight autoantibodies that are released by the immune system in response to the presence of prostate cancer and developed an algorithm that can be used to indicate a relatively high or low risk of prostate cancer, particularly for patients with intermediate (4.0 to 10 ng/mL) PSA levels.

These findings offer insight into the opportunity for advancing the diagnosis of prostate cancer. To read the full paper published in the Open Access Text (OAT), an independent scientific publisher, please go to: